Ken Griffin In8 Bio, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in In8 Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 29,450 shares of INAB stock, worth $68,618. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,450Holding current value
$68,618% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding INAB
# of Institutions
28Shares Held
21.6MCall Options Held
0Put Options Held
0-
Bios Capital Management, LP Fort Worth, TX8.6MShares$20 Million1.8% of portfolio
-
Franklin Resources Inc San Mateo, CA5.7MShares$13.3 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.08MShares$4.85 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.8MShares$4.2 Million0.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.45MShares$3.38 Million0.13% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $57.1M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...